{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:59:00Z","timestamp":1781060340008,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00520-026-10813-9","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:03:47Z","timestamp":1779451427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative nausea and vomiting as a predictor of chemotherapy-induced nausea and vomiting in gynecologic cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"34","author":[{"given":"Senri","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Kikuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Bomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Hayasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"10","key":"10813_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA, ESMO Guidelines Committee (2023) Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(10):833\u2013848. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.011","journal-title":"Ann Oncol"},{"issue":"9","key":"10813_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","volume":"33","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N, ESMO Guidelines Committee (2022) Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(9):860\u2013877. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.009","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10813_CR3","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","volume":"28","author":"C Marth","year":"2017","unstructured":"Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, ESMO Guidelines Committee (2017) Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):iv72\u2013iv83. https:\/\/doi.org\/10.1093\/annonc\/mdx220","journal-title":"Ann Oncol"},{"issue":"6","key":"10813_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830","journal-title":"J Clin Oncol"},{"issue":"3","key":"10813_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/00000542-199909000-00022","volume":"91","author":"CC Apfel","year":"1999","unstructured":"Apfel CC, L\u00e4\u00e4r\u00e4 E, Koivuranta M, Greim CA, Roewer N (1999) A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 91(3):693\u2013700. https:\/\/doi.org\/10.1097\/00000542-199909000-00022","journal-title":"Anesthesiology"},{"issue":"5","key":"10813_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/bja\/aes276","volume":"109","author":"CC Apfel","year":"2012","unstructured":"Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, Zhang K, Cakmakkaya OS (2012) Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 109(5):742\u2013753. https:\/\/doi.org\/10.1093\/bja\/aes276","journal-title":"Br J Anaesth"},{"issue":"6","key":"10813_CR7","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1213\/01.ANE.0000219597.16143.4D","volume":"102","author":"TJ Gan","year":"2006","unstructured":"Gan TJ (2006) Risk factors for postoperative nausea and vomiting. Anesth Analg 102(6):1884\u20131898. https:\/\/doi.org\/10.1213\/01.ANE.0000219597.16143.4D","journal-title":"Anesth Analg"},{"issue":"1","key":"10813_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/sja.SJA_401_19","volume":"14","author":"M Amirshahi","year":"2020","unstructured":"Amirshahi M, Behnamfar N, Badakhsh M, Rafiemanesh H, Keikhaie KR, Sheyback M, Sari M (2020) Prevalence of postoperative nausea and vomiting: a systematic review and meta-analysis. Saudi J Anaesth 14(1):48\u201356. https:\/\/doi.org\/10.4103\/sja.SJA_401_19","journal-title":"Saudi J Anaesth"},{"issue":"5","key":"10813_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47(5):839-848.e4. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.06.012","journal-title":"J Pain Symptom Manage"},{"key":"10813_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, Yoo I (2020) Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol 11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329","journal-title":"Front Pharmacol"},{"issue":"23","key":"10813_CR11","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"issue":"1","key":"10813_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1188\/09.CJON.54-64","volume":"13","author":"R Hawkins","year":"2009","unstructured":"Hawkins R, Grunberg S (2009) Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs 13(1):54\u201364. https:\/\/doi.org\/10.1188\/09.CJON.54-64","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10813_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jand.2015.10.020","volume":"116","author":"W Marx","year":"2016","unstructured":"Marx W, Kiss N, McCarthy AL, McKavanagh D, Isenring L (2016) Chemotherapy-induced nausea and vomiting: a narrative review to inform dietetics practice. J Acad Nutr Diet 116(5):819\u2013827. https:\/\/doi.org\/10.1016\/j.jand.2015.10.020","journal-title":"J Acad Nutr Diet"},{"issue":"7","key":"10813_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S1470-2045(25)00233-5","volume":"26","author":"M Saito","year":"2025","unstructured":"Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N (2025) Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 26(7):960\u2013970. https:\/\/doi.org\/10.1016\/S1470-2045(25)00233-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"10813_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scott\u00e9 F (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"issue":"24","key":"10813_CR16","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"issue":"7","key":"10813_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Eguchi Nakajima T, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K (2024) 2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29(7):873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10813_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, Jordan K, Chow R, Herrstedt J (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32(1):45. https:\/\/doi.org\/10.1007\/s00520-023-08222-3","journal-title":"Support Care Cancer"},{"issue":"2","key":"10813_CR19","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","volume":"25","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K, Tamura K (2020) A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist 25(2):e373\u2013e380. https:\/\/doi.org\/10.1634\/theoncologist.2019-0292","journal-title":"Oncologist"},{"issue":"4","key":"10813_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109(4):859\u2013865. https:\/\/doi.org\/10.1038\/bjc.2013.400","journal-title":"Br J Cancer"},{"issue":"3","key":"10813_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21(3):491\u2013497. https:\/\/doi.org\/10.1007\/s10147-015-0928-y","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10813_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28(6):1260\u20131267. https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"},{"issue":"25","key":"10813_CR23","doi-asserted-by":"publisher","first-page":"04964","DOI":"10.1016\/j.annonc.2025.10.017","volume":"S0923\u20137534","author":"A Molassiotis","year":"2025","unstructured":"Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, Stimamiglio V, Alonzi A, Olivari Tilola S, Bonizzoni E, Brozos V\u00e1zquez E, Buchler T, Cheng Y, Christoph DC, Garc\u00eda Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanov\u00e1 M, Aapro M (2025) Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. Ann Oncol S0923\u20137534(25):04964\u201304966. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.017","journal-title":"Ann Oncol"},{"issue":"3","key":"10813_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, Yamamoto S, Arai T, Sakurai M, Mori M, Nakamura K, Kado N, Murase S, Shimaoka R, Suzuki A, Morishige KI (2020) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol 156(3):629\u2013635. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.004","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10813_CR25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.24.00278","volume":"42","author":"N Inui","year":"2024","unstructured":"Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T (2024) Olanzapine plus triple antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting: a randomized, double-blind, placebo-controlled phase III trial. J Clin Oncol 42(23):2780\u20132789. https:\/\/doi.org\/10.1200\/JCO.24.00278","journal-title":"J Clin Oncol"},{"issue":"8","key":"10813_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26076","volume":"7","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, Srinivas S, Kapoor A, Mishra BK, Gupta A, Sansar B, Pal V, Pandey A, Bonda A, Siripurapu I, Muddu VK, Kannan S, Chaugule D, Patil R, Parulekar M, Dhanawat A, Trikha M, Ghosh J, Noronha V, Menon N, Patil V, Prabhash K, Olver I (2024) Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open 7(8):e2426076. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26076","journal-title":"JAMA Netw Open"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10813-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:29:47Z","timestamp":1781058587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10813-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10813"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10813-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan and the Declaration of Helsinki (1964) and its later amendments. The study protocol was reviewed and approved by the Institutional Review Board of Gifu University Graduate School of Medicine (Approval No. 2023-291).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Because this was a retrospective study using only pre-existing data extracted from the electronic health record and involved no direct contact with patients, the requirement for written informed consent was waived by the Institutional Review Board. In accordance with institutional policy, information regarding the study and procedures for opting out was posted on the hospital website to ensure that patients had the opportunity to decline participation. All data were fully de-identified prior to analysis to protect privacy and confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Hirotoshi Iihara has received consulting fees from Astellas Pharma, Daiichi Sankyo, and Taiho Pharmaceutical. He has also received honoraria for lectures from Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Nippon Kayaku, Ohara Pharmaceutical, Sawai Pharmaceutical, and Taiho Pharmaceutical. Daichi Watanabe has received honoraria for lectures from Chugai Pharmaceutical. Akio Suzuki has received grants from Nippon Kayaku, Chugai Pharmaceutical, Japan Blood Products Organization, Mochida Pharmaceutical, and Asahi Kasei Pharma. He has also received honoraria for lectures from Tsumura, Daiichi Sankyo, Towa Pharmaceutical, Nippon Kayaku, Mochida Pharmaceutical, EA Pharma, Yakult Honsha, Chugai Pharmaceutical, AbbVie, Eisai, and Toa Eiyo. All other authors declare no conflicts of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"568"}}